Antacids Market Report by Drug Class (Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Pro-Motility Agents), Formulation Type (Tablet, Liquid, Powder, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Region 2024-2032

Antacids Market Report by Drug Class (Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Pro-Motility Agents), Formulation Type (Tablet, Liquid, Powder, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112024A5082
Buy Now

Antacids Market Overview:

The global antacids market size reached US$ 6.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.5 Billion by 2032, exhibiting a growth rate (CAGR) of 3.5% during 2024-2032. The market is experiencing growth mainly because of the expansion of retail pharmacies, preference for OTC drugs, and rising number of patients experiencing gastroesophageal reflux disease (GERD) are impelling the growth of the market.

Report Attribute 
Key Statistics
Base Year
2023
Forecast Years
2024-2032
Historical Years
2018-2023
Market Size in 2023
US$ 6.9 Billion
Market Forecast in 2032
US$ 9.5 Billion
Market Growth Rate (2024-2032) 3.5%


Antacids Market Analysis:

  • Major Market Drivers: People suffering from GERD is increasing around the world, which is catalyzing the demand for antacids. This represents one of the key factors propelling the market growth.
  • Key Market Trends: The launch of flavored and chewable antacids drugs by key players like watermelon mint, fruity cereals, and strawberry milkshake is positively impacting the antacids market revenue.
  • Geographical Trends: Asia Pacific is the largest regional market for antacids because of the rising healthcare expenditure, aging population, and healthcare sector expansion.
  • Key Players: Some of the major market players in the antacids industry include Abbott Laboratories, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Procter & Gamble Company, Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited., among many others.
  • Challenges and Opportunities: Challenges in the antacids market are the presence of alternative treatment for acid reflux, while opportunities lie in emerging markets and innovative formulations to treat digestive issues.
     

Global Antacids Market Report


Antacids Market Trends:

Gastroesophageal reflux disease’s (GERD) impact

783.95 million people were impacted by GERD in 2019 claimed by the report of the National Library of Medicine 2022. The more people going through the suffering of GERD, the more it is driving the demand for antacids. The best treatment for acidity is thought to be antacids because of their several qualities. Individuals are aware about the quick relief provided by antacids and their easy accessibility is further contributing to the antacids market growth.

Changing demographics because of rising geriatric population

Elderly people are understanding the importance of antacids because of their quick relief qualities from acidity. They are, as a result, a regular consumer or buyer of antacids to manage these digestive issues. It may be said that nations with increased aging population rates can have higher sales of antacids worldwide. As claimed by the World Health Organization’s (WHO) report of 2022, 1 individual out of 6 will be of 60 years in age or over by 2030 and by 2050. The global population of those aged 60 and over will also reach 2.1 billion, up from 1.4 billion in 2020.

Rising reliance on over the counter (OTC) medicines due to their ease of availability

Non-prescribed remedies are highly preferred in the world to cure mild symptoms, which is catalyzing the antacids demand. Antacids are easily available via pharmacies, grocery stores, and online platforms and as a result play a crucial role in self-medication purposes. The cost-effectiveness and time saving benefits provided by antacids are making them highly suitable for people nowadays. The IMARC Group’s research report mentions that the global market for over the counter (OTC) drugs will reach US$ 275.9 Billion by 2032.

 

 
 

 

Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

Antacids Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on drug class, formulation type, and distribution channel.

Breakup by Drug Class:

 

 
 

 

Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

  • Proton Pump Inhibitors
  • H2 Antagonist
  • Acid Neutralizers
  • Pro-Motility Agents
     

Proton pump inhibitors accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes proton pump inhibitors, H2 antagonist, acid neutralizers, & pro-motility agents. According to the report, proton pump inhibitors represent the largest segment.

Proton pump inhibitors are so effective and reliable that everyone wants them to cut down on stomach acid and indigestion. Healthcare professionals prescribed them as per the severity of acid reflux, leading to their higher sales. Key players are expanding their market as they know people are gaining knowledge about the positive impact of proton pump inhibitors in the body. For instance, Daewon Pharmaceutical introduced its first proton pump inhibitor medicine in Korea in 2022, known as Escorten.

Breakup by Formulation Type:

  • Tablet
  • Liquid
  • Powder
  • Others
     

Tablet holds the largest share of the industry

A detailed breakup and analysis of the market based on the formulation type have also been provided in the report. This includes tablet, liquid, powder, and others. According to the report, tablet accounts for the majority of the market share.

Easy storage, transportation, and administration are some benefits provided by tablets make them highly preferable among individuals. Tablets are hassle-free, as they can be easily consumed with water anywhere or on the go. Whether at office, home, or travel, people can get quick relief from acidity or indigestion through tablet drugs. The extended shelf life of tablets is viewed as another benefit compared to liquid or powder formulation type. Various tablets formulations present in the antacids market like chewable, delayed release, and effervescent are further creating a strong consumer base.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
     

Retail pharmacies represent the leading market segment 

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, and others. According to the report, retail pharmacies dominate the market.

In the first place, cities, suburbs, and rural areas all have numerous retail pharmacies around the world. Antacids as OTC drugs are highly popular & retail pharmacies are a significant outlet to purchase antacids. Secondly, the inclusion of a wide variety of antacids drugs in retail pharmacies can cater to several patients according to their preferences and demands. Thirdly, the focus of leading competitors in the retail pharmacy market on acquisition & expansion to increase their reach. The acquisition of Pharmaca by Medly Pharmacy in 2021 to deliver 360-degrees pharmacy services is one such example.

Breakup by Region:

 

 
 

 

To get more information on the regional analysis of this market, Request Sample

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Asia Pacific leads the market, accounting for the largest antacids market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific enjoys the leading position in the market.

The densely populated countries like India and China are the largest markets for antacids in this region, as these countries are undergoing lifestyle shifts and Western food habits, which generally results in acid reflux and indigestion. Moreover, aging population in the region is viewed as an antacids market recent opportunities due to their high susceptibility to digestive issues. In line with this, lots of key players are present in the Asia Pacific region that are highly competitive and focus on partnerships and acquisition to expand their market. This was done by Dr. Reddy’s Laboratories, a pharma company in India, when it acquired MenoLabs from Amyris Inc. in 2024 to cater to the evolving needs of people in the Asia Pacific region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major antacids companies have also been provided. Some of the major market players in the antacids industry include:

  • Abbott Laboratories
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Dr. Reddy’s Laboratories Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Pfizer Inc.
  • Procter & Gamble Company
  • Reckitt Benckiser Group PLC
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited.
     

(Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.)

The development of new formulations and product variants is done by key players through research and development (R&D) activities. They are introducing antacid drugs with flavors such as Fruity Cereal to meet the evolving demands of consumers. Top companies are taking advantage of elevated awareness about gastrointestinal health among people in developing countries. They are also eyeing on acquiring small businesses in the market while creating opportunities via antacids market recent developments. Using the digital health solutions is the main help method, enabling them to provide better health results. One such example was presented by AstraZeneca in November 2023, which it launched Evinova, a health-tech business, to offer advanced digital health solutions.

Antacids Market News:

  • In 2022: Zydus Lifesciences received approval from the USFDA to introduce Famotidine tablets, which is a histamine H2 receptor blocker and plays a vital role in reducing acid amount in the stomach.


Antacids Market Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Scope of the Report Exploration of Historical Trends and Antacids Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
  • Drug Class
  • Formulation Type
  • Distribution Channel
  • Region
Drug Classes Covered Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Pro-Motility Agents
Formulation Types Covered Tablet, Liquid, Powder, Others
Distribution Channels Covered Hospital Pharmacies, Retail Pharmacies, Others
Regions Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Abbott Laboratories, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Procter & Gamble Company, Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited., etc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Key Benefits for Stakeholders:

  • IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the antacids market from 2018-2032.
  • The research report provides the latest information on the market drivers, challenges, and opportunities in the global antacids market.
  • The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
  • Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the antacids industry and its attractiveness.
  • The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

Key Questions Answered in This Report

The global antacids market was valued at US$ 6.9 Billion in 2023.

We expect the global antacids market to exhibit a CAGR of 3.5% during 2024-2032.

The rising demand for antacids in relieving inflammation, swelling, pain, and irritation associated with heartburn, along with the introduction of raft-forming antacids that are safe and have strong medications, which provide higher efficacy and increased duration of action, is primarily driving the global antacids market.

The sudden outbreak of the COVID-19 pandemic had led to the growing number of R&D activities pertaining to specialty generic drugs for combating the spread of the coronavirus infection, thereby negatively impacting the global market for antacids.

Based on the drug class, the global antacids market can be categorized into proton pump inhibitors, H2 antagonist, acid neutralizers, and pro-motility agents. Currently, proton pump inhibitors hold the majority of the total market share.

Based on the formulation type, the global antacids market has been segmented into tablet, liquid, powder, and others. Among these, tablet currently exhibits a clear dominance in the market.

Based on the distribution channel, the global antacids market can be bifurcated into hospital pharmacies, retail pharmacies, and others. Currently, retail pharmacies account for the largest market share.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where Asia-Pacific currently dominates the global market.

Some of the major players in the global antacids market include Abbott Laboratories, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Procter & Gamble Company, Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Company Limited.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Antacids Market Report by Drug Class (Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Pro-Motility Agents), Formulation Type (Tablet, Liquid, Powder, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Region 2024-2032
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More